While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak competitive positioning.

Cash flow is valuable, but it’s not everything - StockStory helps you identify the companies that truly put it to work. Keeping that in mind, here are three cash-producing companies that don’t make the cut and some better opportunities instead.

Wyndham (WH)

Trailing 12-Month Free Cash Flow Margin: 22.5%

Established in 1981, Wyndham (NYSE: WH) is a global hotel franchising company with over 9,000 hotels across nearly 95 countries on six continents.

Why Do We Steer Clear of WH?

1. Softer revenue per room over the past two years suggests it might have to invest in new amenities such as restaurants and bars to attract customers
2. Low returns on capital reflect management’s struggle to allocate funds effectively, and its decreasing returns suggest its historical profit centers are aging
3. Diminishing returns on capital from an already low starting point show that neither management’s prior nor current bets are going as planned

Wyndham’s stock price of $87.54 implies a valuation ratio of 18.2x forward P/E. Read our free research report to see why you should think twice about including WH in your portfolio.

Latham (SWIM)

Trailing 12-Month Free Cash Flow Margin: 4.8%

Started as a family business, Latham (NASDAQ: SWIM) is a global designer and manufacturer of in-ground residential swimming pools and related products.

Why Do We Avoid SWIM?

1. Lackluster 6.2% annual revenue growth over the last five years indicates the company is losing ground to competitors
2. Poor expense management has led to an operating margin of 4.6% that is below the industry average
3. Free cash flow margin is expected to remain in place over the coming year

Latham is trading at $6.03 per share, or 30.5x forward P/E. To fully understand why you should be careful with SWIM, check out our full research report (it’s free).

Pediatrix Medical Group (MD)

Trailing 12-Month Free Cash Flow Margin: 13.2%

With a network of approximately 2,620 affiliated physicians caring for some of the most vulnerable patients, Pediatrix Medical Group (NYSE: MD) provides specialized physician services focused on neonatal, maternal-fetal, pediatric cardiology and other pediatric subspecialty care across 37 states.

Why Are We Hesitant About MD?

1. Sales tumbled by 2% annually over the last two years, showing market trends are working against its favor during this cycle
2. Projected sales for the next 12 months are flat and suggest demand will be subdued
3. Shrinking returns on capital from an already weak position reveal that neither previous nor ongoing investments are yielding the desired results

At $22.04 per share, Pediatrix Medical Group trades at 10.1x forward P/E. If you’re considering MD for your portfolio, see our FREE research report to learn more.

Stocks We Like More

WHILE YOU’RE HERE: Top 9 Market-Beating Stocks. The best stocks don't just beat the market once. They do it again. And again. Robust revenue growth, rising free cash flow, returns on capital that leave their competition in the dust. The market has already rewarded these businesses.

But our AI platform says the party isn't over. Find out which 9 stocks made the cut this week — FREE. Get Our Top 9 Market-Beating Stocks for Free HERE.

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.